A Cross-sectional Survey of Colorectal Cancer Patients in Different Age Groups
Launched by WANG GUIYU · Nov 21, 2023
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to better understand colorectal cancer by comparing patients of different ages. Researchers want to find out how symptoms vary among younger and older patients, if there's a genetic link in families, and how the cancer's characteristics differ based on age. This information could help doctors improve prevention and treatment strategies for colorectal cancer, making them more effective for different age groups.
To participate in this study, you need to be at least 18 years old and have been diagnosed with colorectal cancer that requires surgery. You also need to be willing to take part in the survey. If you decide to join, you'll be asked questions about your experience with the disease. Your involvement could provide valuable insights that might help future patients. If you have any concerns or need more information, the research team is there to support you.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adults aged 18 years and older with a pathologic diagnosis of colorectal cancer;
- • 2. Undergoing surgical treatment of the primary lesion;
- • 3. Voluntary participation of patients.
- Exclusion Criteria:
- • 1. Do not agree to participate in the survey or withdraw informed consent
- • 2. Patients did not receive surgical treatment or did not undergo pathologic examination
About Wang Guiyu
Wang Guiyu is a dedicated clinical trial sponsor focused on advancing medical research and innovation. With a commitment to enhancing patient care and outcomes, the organization specializes in the design, implementation, and management of clinical trials across various therapeutic areas. Wang Guiyu leverages a collaborative approach, working closely with healthcare professionals, regulatory bodies, and research institutions to ensure compliance and integrity throughout the research process. By prioritizing ethical standards and patient safety, the sponsor aims to contribute to the development of effective therapies that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Harbin, Heilongjiang, China
Patients applied
Trial Officials
Ye Tian, Prof.
Study Chair
Second Affiliated Hospital of Harbin Medical University Ethics Committee
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported